Investigations and management of chronic cough: a 2020 update from the European Respiratory Society Chronic Cough Task Force

Chronic cough affects approximately 10% of the general population, is highest amongst people aged 50 to 60 years, and is twice as common in women than men. It is described to last 8 weeks or longer in adults and does not respond well to treatment with over-the-counter medications and those targeting...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Polskie archiwum medycyny wewne̦trznej 2020-09, Vol.130 (9), p.789-795
Hauptverfasser: Farooqi, Mohammed A M, Cheng, Vicky, Wahab, Mustafaa, Shahid, Izza, O'Byrne, Paul M, Satia, Imran
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 795
container_issue 9
container_start_page 789
container_title Polskie archiwum medycyny wewne̦trznej
container_volume 130
creator Farooqi, Mohammed A M
Cheng, Vicky
Wahab, Mustafaa
Shahid, Izza
O'Byrne, Paul M
Satia, Imran
description Chronic cough affects approximately 10% of the general population, is highest amongst people aged 50 to 60 years, and is twice as common in women than men. It is described to last 8 weeks or longer in adults and does not respond well to treatment with over-the-counter medications and those targeting potential associated conditions. This is a debilitating condition with physical, social, and psychological consequences. The purpose of this review was to highlight the key messages on the management of chronic cough from the task force commissioned by the European Respiratory Society. The assessment of patients with chronic cough should include a thorough detailed history and examination to identify potential causes. The impact and severity can be assessed in a clinic using questionnaires. Potential causes of the condition vary and include, for example, angiotensin‑converting enzyme inhibitors, smoking, asthma, nonasthmatic eosinophilic bronchitis, gastroesophageal reflux disease, and upper airways cough syndrome. In many patients, coughing is persistent despite optimum medical therapy of the underlying medical condition and is hence referred to as refractory chronic cough. In some cases, no cause can be found and the cough is classified as unexplained chronic cough. If treatment of any underlying disease is unsuccessful at controlling cough, then neuromodulatory treatment such as a low‑dose opioid, gabapentin, pregabalin or speech and language therapy may be considered. There is no licensed treatment for chronic cough, but a new class of treatment targeting the purinergic P2X3 receptor is currently in phase 2 and 3 of development.
doi_str_mv 10.20452/pamw.15484
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2420633675</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2420633675</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-a375fdfd4f2d1c9661538c2288cd0a3848a5651612ec2861f3c95e98c0629abf3</originalsourceid><addsrcrecordid>eNo1kM1LwzAchoMgbk5P3iVHL535bupNyqaDgaDzXH5Lk626NjVJlYF_vBPn6b08PPC8CF1RMmVESHbbQ_s1pVJocYLGVBd5VgjNR-g8xjdCVMF1foZGnCmWSyrG6HvRfdqYmg2kxncRQ1fjFjrY2NZ2CXuHzTb4rjHY-GGzvcOAGWEED30NyWIXfIvT1uLZEHxvocPPNvZNgOTDHr9409i0x-VRUf4q8AriO577YOwFOnWwi_byuBP0Op-tysds-fSwKO-XWc8oTRnwXLra1cKxmppCKSq5NoxpbWoCXAsNUkmqKLOGaUUdN4W0hTZEsQLWjk_QzZ-3D_5jOORWbRON3e2gs36IFROMKM5VLg_o9REd1q2tqz40LYR99f8Y_wEzDWuD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2420633675</pqid></control><display><type>article</type><title>Investigations and management of chronic cough: a 2020 update from the European Respiratory Society Chronic Cough Task Force</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Farooqi, Mohammed A M ; Cheng, Vicky ; Wahab, Mustafaa ; Shahid, Izza ; O'Byrne, Paul M ; Satia, Imran</creator><creatorcontrib>Farooqi, Mohammed A M ; Cheng, Vicky ; Wahab, Mustafaa ; Shahid, Izza ; O'Byrne, Paul M ; Satia, Imran</creatorcontrib><description>Chronic cough affects approximately 10% of the general population, is highest amongst people aged 50 to 60 years, and is twice as common in women than men. It is described to last 8 weeks or longer in adults and does not respond well to treatment with over-the-counter medications and those targeting potential associated conditions. This is a debilitating condition with physical, social, and psychological consequences. The purpose of this review was to highlight the key messages on the management of chronic cough from the task force commissioned by the European Respiratory Society. The assessment of patients with chronic cough should include a thorough detailed history and examination to identify potential causes. The impact and severity can be assessed in a clinic using questionnaires. Potential causes of the condition vary and include, for example, angiotensin‑converting enzyme inhibitors, smoking, asthma, nonasthmatic eosinophilic bronchitis, gastroesophageal reflux disease, and upper airways cough syndrome. In many patients, coughing is persistent despite optimum medical therapy of the underlying medical condition and is hence referred to as refractory chronic cough. In some cases, no cause can be found and the cough is classified as unexplained chronic cough. If treatment of any underlying disease is unsuccessful at controlling cough, then neuromodulatory treatment such as a low‑dose opioid, gabapentin, pregabalin or speech and language therapy may be considered. There is no licensed treatment for chronic cough, but a new class of treatment targeting the purinergic P2X3 receptor is currently in phase 2 and 3 of development.</description><identifier>EISSN: 1897-9483</identifier><identifier>DOI: 10.20452/pamw.15484</identifier><identifier>PMID: 32627514</identifier><language>eng</language><publisher>Poland</publisher><subject>Adult ; Asthma - drug therapy ; Bronchitis, Chronic ; Chronic Disease ; Cough - drug therapy ; Gastroesophageal Reflux - complications ; Gastroesophageal Reflux - drug therapy ; Humans ; Male ; Middle Aged</subject><ispartof>Polskie archiwum medycyny wewne̦trznej, 2020-09, Vol.130 (9), p.789-795</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32627514$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Farooqi, Mohammed A M</creatorcontrib><creatorcontrib>Cheng, Vicky</creatorcontrib><creatorcontrib>Wahab, Mustafaa</creatorcontrib><creatorcontrib>Shahid, Izza</creatorcontrib><creatorcontrib>O'Byrne, Paul M</creatorcontrib><creatorcontrib>Satia, Imran</creatorcontrib><title>Investigations and management of chronic cough: a 2020 update from the European Respiratory Society Chronic Cough Task Force</title><title>Polskie archiwum medycyny wewne̦trznej</title><addtitle>Pol Arch Intern Med</addtitle><description>Chronic cough affects approximately 10% of the general population, is highest amongst people aged 50 to 60 years, and is twice as common in women than men. It is described to last 8 weeks or longer in adults and does not respond well to treatment with over-the-counter medications and those targeting potential associated conditions. This is a debilitating condition with physical, social, and psychological consequences. The purpose of this review was to highlight the key messages on the management of chronic cough from the task force commissioned by the European Respiratory Society. The assessment of patients with chronic cough should include a thorough detailed history and examination to identify potential causes. The impact and severity can be assessed in a clinic using questionnaires. Potential causes of the condition vary and include, for example, angiotensin‑converting enzyme inhibitors, smoking, asthma, nonasthmatic eosinophilic bronchitis, gastroesophageal reflux disease, and upper airways cough syndrome. In many patients, coughing is persistent despite optimum medical therapy of the underlying medical condition and is hence referred to as refractory chronic cough. In some cases, no cause can be found and the cough is classified as unexplained chronic cough. If treatment of any underlying disease is unsuccessful at controlling cough, then neuromodulatory treatment such as a low‑dose opioid, gabapentin, pregabalin or speech and language therapy may be considered. There is no licensed treatment for chronic cough, but a new class of treatment targeting the purinergic P2X3 receptor is currently in phase 2 and 3 of development.</description><subject>Adult</subject><subject>Asthma - drug therapy</subject><subject>Bronchitis, Chronic</subject><subject>Chronic Disease</subject><subject>Cough - drug therapy</subject><subject>Gastroesophageal Reflux - complications</subject><subject>Gastroesophageal Reflux - drug therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><issn>1897-9483</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kM1LwzAchoMgbk5P3iVHL535bupNyqaDgaDzXH5Lk626NjVJlYF_vBPn6b08PPC8CF1RMmVESHbbQ_s1pVJocYLGVBd5VgjNR-g8xjdCVMF1foZGnCmWSyrG6HvRfdqYmg2kxncRQ1fjFjrY2NZ2CXuHzTb4rjHY-GGzvcOAGWEED30NyWIXfIvT1uLZEHxvocPPNvZNgOTDHr9409i0x-VRUf4q8AriO577YOwFOnWwi_byuBP0Op-tysds-fSwKO-XWc8oTRnwXLra1cKxmppCKSq5NoxpbWoCXAsNUkmqKLOGaUUdN4W0hTZEsQLWjk_QzZ-3D_5jOORWbRON3e2gs36IFROMKM5VLg_o9REd1q2tqz40LYR99f8Y_wEzDWuD</recordid><startdate>20200930</startdate><enddate>20200930</enddate><creator>Farooqi, Mohammed A M</creator><creator>Cheng, Vicky</creator><creator>Wahab, Mustafaa</creator><creator>Shahid, Izza</creator><creator>O'Byrne, Paul M</creator><creator>Satia, Imran</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20200930</creationdate><title>Investigations and management of chronic cough: a 2020 update from the European Respiratory Society Chronic Cough Task Force</title><author>Farooqi, Mohammed A M ; Cheng, Vicky ; Wahab, Mustafaa ; Shahid, Izza ; O'Byrne, Paul M ; Satia, Imran</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-a375fdfd4f2d1c9661538c2288cd0a3848a5651612ec2861f3c95e98c0629abf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Asthma - drug therapy</topic><topic>Bronchitis, Chronic</topic><topic>Chronic Disease</topic><topic>Cough - drug therapy</topic><topic>Gastroesophageal Reflux - complications</topic><topic>Gastroesophageal Reflux - drug therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Farooqi, Mohammed A M</creatorcontrib><creatorcontrib>Cheng, Vicky</creatorcontrib><creatorcontrib>Wahab, Mustafaa</creatorcontrib><creatorcontrib>Shahid, Izza</creatorcontrib><creatorcontrib>O'Byrne, Paul M</creatorcontrib><creatorcontrib>Satia, Imran</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Polskie archiwum medycyny wewne̦trznej</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Farooqi, Mohammed A M</au><au>Cheng, Vicky</au><au>Wahab, Mustafaa</au><au>Shahid, Izza</au><au>O'Byrne, Paul M</au><au>Satia, Imran</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Investigations and management of chronic cough: a 2020 update from the European Respiratory Society Chronic Cough Task Force</atitle><jtitle>Polskie archiwum medycyny wewne̦trznej</jtitle><addtitle>Pol Arch Intern Med</addtitle><date>2020-09-30</date><risdate>2020</risdate><volume>130</volume><issue>9</issue><spage>789</spage><epage>795</epage><pages>789-795</pages><eissn>1897-9483</eissn><abstract>Chronic cough affects approximately 10% of the general population, is highest amongst people aged 50 to 60 years, and is twice as common in women than men. It is described to last 8 weeks or longer in adults and does not respond well to treatment with over-the-counter medications and those targeting potential associated conditions. This is a debilitating condition with physical, social, and psychological consequences. The purpose of this review was to highlight the key messages on the management of chronic cough from the task force commissioned by the European Respiratory Society. The assessment of patients with chronic cough should include a thorough detailed history and examination to identify potential causes. The impact and severity can be assessed in a clinic using questionnaires. Potential causes of the condition vary and include, for example, angiotensin‑converting enzyme inhibitors, smoking, asthma, nonasthmatic eosinophilic bronchitis, gastroesophageal reflux disease, and upper airways cough syndrome. In many patients, coughing is persistent despite optimum medical therapy of the underlying medical condition and is hence referred to as refractory chronic cough. In some cases, no cause can be found and the cough is classified as unexplained chronic cough. If treatment of any underlying disease is unsuccessful at controlling cough, then neuromodulatory treatment such as a low‑dose opioid, gabapentin, pregabalin or speech and language therapy may be considered. There is no licensed treatment for chronic cough, but a new class of treatment targeting the purinergic P2X3 receptor is currently in phase 2 and 3 of development.</abstract><cop>Poland</cop><pmid>32627514</pmid><doi>10.20452/pamw.15484</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 1897-9483
ispartof Polskie archiwum medycyny wewne̦trznej, 2020-09, Vol.130 (9), p.789-795
issn 1897-9483
language eng
recordid cdi_proquest_miscellaneous_2420633675
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Adult
Asthma - drug therapy
Bronchitis, Chronic
Chronic Disease
Cough - drug therapy
Gastroesophageal Reflux - complications
Gastroesophageal Reflux - drug therapy
Humans
Male
Middle Aged
title Investigations and management of chronic cough: a 2020 update from the European Respiratory Society Chronic Cough Task Force
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A35%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Investigations%20and%20management%20of%20chronic%20cough:%20a%202020%20update%20from%20the%20European%20Respiratory%20Society%20Chronic%20Cough%20Task%20Force&rft.jtitle=Polskie%20archiwum%20medycyny%20wewne%CC%A6trznej&rft.au=Farooqi,%20Mohammed%20A%20M&rft.date=2020-09-30&rft.volume=130&rft.issue=9&rft.spage=789&rft.epage=795&rft.pages=789-795&rft.eissn=1897-9483&rft_id=info:doi/10.20452/pamw.15484&rft_dat=%3Cproquest_pubme%3E2420633675%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2420633675&rft_id=info:pmid/32627514&rfr_iscdi=true